Background. Little is known about how new-generation adenosine triphosphate-competitive mechanistic target of rapamycin (mTOR) kinase inhibitors affect immunity and allograft rejection. Methods. mTOR complex (C) 1 and 2 signaling in dendritic cells and T cells was analyzed by Western blotting, whereas immune cell populations in normal and heart allograft recipient mice were analyzed by flow cytometry. Alloreactive T cell proliferation was quantified in mixed leukocyte reaction; intracellular cytokine production and serum antidonor IgG levels were determined by flow analysis and immunofluorescence staining used to detect IgG in allografts.
T he mechanistic target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that drives organelle and cell growth 1,2 through upregulation of glycolysis to fuel nucleotide, protein, and lipid synthesis. mTOR functions as a component of at least 2 distinct multiprotein complexes,-mTOR complex 1 (mTORC1) and mTORC2. 3, 4 Although both complexes include mammalian lethal with SEC13 protein 8 and DEP domain-containing mTOR-interacting protein, mTORC1 uniquely associates with regulatory associated protein of mTOR and proline-rich Akt substrate of 40 kDa. In contrast, mTORC2 associates with Rictor (rapamycin [RAPA]-insensitive companion of mTOR), mSIN1 (mammalian stress-activated protein kinase-interacting protein 1) and Protor (protein observed with Rictor). Although mTORC1 has been implicated in regulation of nucleotide and protein synthesis, as well as autophagy, much less is known about the functions of mTORC2. Recently, however, mTORC2 has been implicated in regulation of cell growth, proliferation, survival, and cytoskeletal organization, as well as sodium handling in the kidney. [5] [6] [7] There have been important recent advances in understanding of how mTOR complexes regulate immune cell differentiation and function. 8 Thus, genetic deletion of either mTORC1 or mTORC2 in T cells has revealed that T helper (Th) 1 and Th17 differentiation is selectively regulated by mTORC1, whereas Th2 development is mTORC2-dependent. 9, 10 Furthermore, inhibition of both mTORC1 and mTORC2 favors regulatory T (Treg) cell development more than inhibition of either complex alone. In separate studies, small hairpin RNA vectors targeting regulatory associated protein of mTOR (mTORC1) induce T follicular B helper (Tfh) cell differentiation at the expense of Th1 cells, whereas Rictor deletion promotes Th1 cells, with minimal effect on Tfh cells. 11 Although less is known concerning how mTOR impacts B cell function, deletion of Rictor in B cells causes marked deficiencies in mature follicular, marginal zone and B1a B cells with consequent effects on antibody (Ab) responses in vivo. 12 The immunosuppressive prodrug RAPA is an allosteric inhibitor of mTOR that mediates it effects indirectly via interaction with the immunophilin FK506 binding protein (FKBP) 12 and formation of a drug-immunophilin complex that directly binds the FKBP-RAPA-binding (FRB) domain of mTOR. 13 Although the assembly of mTORC1 is RAPA-sensitive, mTORC2 is insensitive to RAPA. Recent studies in yeast demonstrating that the C terminal part of Avo3, a subunit unique to mTORC2, prevents RAPA-FKBP12 from accessing the FRB domain 14 may help explain this phenomenon. To overcome shortcomings of RAPA and its analogues (rapalogs) as therapy for advanced malignancies, new generation adenosine triphosphate (ATP)-competitive mTOR inhibitors (TORKinibs) have been developed. By targeting both mTORC1 and mTORC2, these second-generation mTOR inhibitors have been predicted to have more potent antitumor effects. Based on encouraging preclinical results, TORKinibs are being tested in early-phase clinical trials for treatment of advanced solid tumors or multiple myeloma. 15, 16 Although much of our understanding of the effects of these TORKinibs stems from studies in oncology, little is known about their influence on immunity or their potential as immunosuppressive agents. Recently, in a limited proof-of-principle study, 17 we showed that the ATP-competitive mTOR inhibitor AZD8055 could suppress T cell proliferation and prolong graft survival in mice. AZD8055 is no longer in clinical development due to frequently reported elevations in transaminases. However, AZD2014 (Vistusertib), a related compound, with a more favorable pharmacokinetic profile, 18, 19 has entered early-phase trials in advanced malignancy. [19] [20] [21] Here, we examined, for the first time, the influence of AZD2014 (compared with RAPA) on immune cell populations, allograft rejection and underlying cellular and humoral immunity. , and B6.Cg-Tg (Tcra,Tcrb)3Ayr/J (referred to as 1H3.1) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). They were maintained under specific pathogen-free conditions in an American Association for the Accreditation of Laboratory Animal Care-accredited facility. All experiments were performed under an Institutional Animal Care and Use Committee-approved protocol, in accordance with NIH guidelines.
MATERIALS AND METHODS

Mice
Dendritic Cell Generation and Stimulation
Dendritic cell (DC) were generated from freshly-isolated B6 bone marrow (BM) cells, as described. 22 On day 2 of culture, either RAPA (LC Laboratories, Woburn, MA) or AZD2014 (Selleck Chemicals, Houston, TX), prediluted in RPMI-1640, was added at the concentration indicated and refreshed on days 4 and 6. Control cultures with no drug administration were set up in parallel. On day 7, cells were collected, counted and CD11c + cells isolated by anti-CD11c immunomagnetic bead purification (Miltenyi Biotec, Auburn, CA). In some experiments, the DC were stimulated for 16 to 18 hours with lipopolysaccharide (LPS) (Salmonella minnesota, 10 ng/mL; R595, Alexis Biochemicals, San Diego, CA).
T Cell Stimulation and Proliferation
CD3
+ T cells were isolated by negative selection and labeled with Violet Proliferation Dye 450 (VPD450; BD Horizon) as per the manufacturer's instructions. They were stimulated (2 Â 10 5 cells/well) by αCD3/CD28 Dynabeads (Gibco) in 96-well, round-bottom plates in the presence of either RAPA or AZD2014 at a bead-to-cell ratio of 1:2. Cultures were maintained for 72 hours before analysis of cell proliferation by flow cytometry. To assess antidonor reactivity in graft recipients, splenic T cells isolated on day 7 or 21 posttransplant and labeled with VPD450 were stimulated for 5 days with T cell-depleted (Miltenyi) donor (BALB/c) or third-party (C3H) splenocytes (1:1 ratio). Cell proliferation was analyzed by flow cytometry.
Cell Surface and Forkhead Box p3 Staining
Lymphocytes (5-10 Â 10 6 ) were first stained with either Zombie Aqua or Zombie NIR (Biolegend, San Diego, CA) to exclude dead cells. All fluorochrome-conjugated Abs were purchased from eBioscience (San Diego, CA), BD Biosciences (San Jose, CA) or BioLegend and used as described. 23, 24 Cell surface staining of DC was performed as described. 25 For Forkhead box p3 (Foxp3) staining, T cells were fixed and permeabilized using Foxp3 Fix Permkit (eBioscience). All data were acquired using an LSR Fortessa flow cytometer and analyzed using FlowJo Version 10.1.
Intracellular Cytokine Staining
These methods are detailed in Methods, SDC (http://links. lww.com/TP/B481).
Western Blots
These methods are detailed in Methods, SDC (http://links. lww.com/TP/B481). [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] ; 500 μg/kg) (Thermo Scientific, Waltham, MA) was injected intraperitoneally (i.p.) Twenty-four h later, the mice received an i.p. injection of either drug vehicle, RAPA or AZD2014 that was repeated for 72 hours until analysis of alloreactive TCR-tg T cell proliferation by flow cytometry.
Heart Transplantation and mTOR Inhibitor Administration BALB/c to B6 heterotopic heart transplantation was performed as described. 26 Graft recipients received a 9-day course of either drug vehicle (i.p. twice daily), RAPA (1 mg/kg per day, i.p. daily) or AZD2014 (10 mg/kg i.p. twice daily). For in vivo administration, RAPA was dissolved in ethanol and diluted in a vehicle containing PBS with 30% polyethylene glycol and 0.5% Tween 80. AZD2014 was dissolved in 65% cremophor EL in ethanol and diluted in the same vehicle. Vehicle-treated control animals received 65% cremophor EL alone prediluted in the same vehicle. Graft survival was monitored by abdominal palpation; rejection was determined by complete cessation of cardiac contraction and confirmed histologically. Groups of recipients were also euthanized on day 7 or 21 posttransplant for immunological analyses.
Donor-Specific AlloAb Measurement
Antidonor and third-party reactive Ab titers were determined as described. 27 Donor (BALB/c) and third-party (C3H) thymocytes (2 Â 10 6 cells per round-bottom well) were incubated with 100 μL of serially diluted serum. Fluorochromeconjugated rat anti-mouse IgG1, IgG2c, and IgG3, as well as biotin-conjugated rat antimouse IgG2b Abs were used at 1:50 to 1:100 dilution (BD Biosciences). Cells were washed and analyzed by flow cytometry.
Histology and Immunofluorescence Staining
These methods are detailed in Methods, SDC, http://links. lww.com/TP/B481.
Statistical Analyses
Results are expressed as means ± 1 SD. Significances of differences between means were determined using either the unpaired, 2-tailed Student t test or 1-way analysis of variance test. Log-rank tests were used to establish the significances of differences between survival curves (GraphPad Prism; San Diego, CA). P < 0.05 was considered significant.
RESULTS
AZD2014, but Not RAPA, Inhibits Both mTORC1 and mTORC2 Signaling
Although previous studies 19, 28 have shown that the ATPcompetitive inhibitor AZD2014 inhibits signaling downstream of both mTORC1 and 2, these studies have been conducted using tumor cell lines. To determine the influence of AZD2014 compared with RAPA on mTOR signaling in DC, purified B6 BM-derived myeloid DCs were incubated with various concentrations of either mTOR inhibitor for 1 hour in the absence or presence of LPS. All in vitro studies were subsequently performed using 11.9 nM RAPA because this dose potently inhibited phosphorylation of S6K at threonine 389 (mTORC1). Figure 1A shows that 500 nM AZD2014 significantly inhibited both 4E-BP1 threonine 37/46 (mTORC1) and Akt Ser473 (mTORC2) phosphorylation in LPS-activated DC compared with LPS-activated control DC. Akt phosphorylation at Ser473 was not significantly affected by any of the concentrations of RAPA tested (11.9, 100, 500, and 1000 nM; data not shown). In contrast, both RAPA and AZD2014 inhibited phosphorylation of S6K at threonine 389 (mTORC1) (data not shown).
AZD2014 Inhibits DC Generation From BM and Both DC and T Cell Responses to Stimulation
We next examined the influence of AZD2014 on DC differentiation from BM. DCs were generated with GM-CSF and IL-4 in the presence of either AZD2014, RAPA, or no drug at concentrations shown to inhibit mTOR signaling. Both agents markedly reduced the yield of DC that could be harvested on 7 days of culture ( Figure 1B ). Coregulatory molecule (CD86 and B7-H1 = programmed death ligand 1) expression (mean fluorescence intensity) by these DC was diminished (although CD86 not significantly) compared with that by cells harvested from control cultures and was similarly diminished after LPS stimulation ( Figure 1C ). Both AZD2014 and RAPA also inhibited the proliferation of αCD3/CD28-stimulated CD4 + and CD8 + T cells when added at the start of 3-day cultures ( Figure 1D ). With respect to both DC differentiation and maturation and T cell proliferative responses, RAPA, used at a concentration 40 times lower, was more potent than AZD2014 in achieving these inhibitory effects.
AZD2014 Administration Markedly Reduces Thymocyte Populations, but Enhances the Incidence of Thymic Treg Cells
Naive B6 mice were injected with either vehicle control, RAPA or AZD2014 for 9 days. As documented previously for RAPA, 29 AZD2014 exerted profound effects on the thymus (Figure 2 ). Thymic size, architecture, and cellularity were all altered significantly by AZD2014 (Figures 2A-D 
Foxp3
+ Treg cell) were all reduced by AZD2014 administration, the percentage of Treg cell within the CD4 compartment was increased significantly by either AZD2014 or RAPA (Figures 2E-H) . Thus, as has been described for RAPA, 30 ,31 dual mTORC1/2 inhibition with AZD2014 enriched for thymic Treg cell, indicating that these cells were more resistant to AZD2014 than effector T cells.
AZD2014 Administration Reduces Immune Cell Populations in Secondary Lymphoid Tissue
Concomitant analysis of the spleen after 9 days of drug administration ( Figure 3) revealed that all T cell subsets, including Tfh and Treg cell, were reduced by AZD2014 as well as RAPA ( Figures 3A-H Figure 3I-L) . Overall, however, the T cell-depleting effects were more moderate than those observed in the thymus. Furthermore, in contrast to the thymus, Treg cell enrichment was not observed in naive mice after either AZD2014 or RAPA administration.
AZD2014 Inhibits Alloreactive CD4 T Cell Proliferation In Vivo
We next determined the influence of AZD2014 on T cell proliferation in response to alloAg stimulation in vivo. 1H3. 
AZD2014 Prolongs Vascularized Heart Allograft Survival
Given the foregoing observations, we hypothesized that AZD2014 monotherapy would prolong organ allograft survival. Given the known effects of mTOR inhibitors on wound healing 32, 33 and evidence mTOR may protect against cardiac ischemia-reperfusion injury, 34, 35 we delayed administration of AZD2014 until day 3 posttransplant (Figure 5A ). Administration of AZD2014 for 9 days significantly prolonged graft survival (median survival time, 25 days versus 9.5 days in vehicle-treated controls ( Figure 5B), associated with marked reductions in graft mononuclear cell infiltration and tissue injury on days 7 and 21 ( Figure 5C ). Median survival time with RAPA administration, however, was greater than that with AZD2014 (100 days; P = 0.05).
AZD2014 and RAPA Differentially Impact Tfh and Treg Cells Posttransplant
We hypothesized that, although naive and effector T cells would be profoundly inhibited by AZD2014 in transplant recipients, Treg and Tfh cell subsets that are known to be less dependent on mTOR-mediated metabolism, 11,36,37 might be relatively spared. We analyzed splenic CD4, CD8, Treg, and Tfh cells 7 and 21 days posttransplant. Seven days + DC generated from B6 mouse BM cells, as described in Materials and Methods, were incubated for 1 hour with either RAPA or AZD2014, then for an additional hour in the absence or presence of LPS (100 ng/mL). The cells were washed, lysed and proteins resolved by SDS-PAGE. The influence of RAPA or AZD2014 on signaling downstream of mTORC1 (4EBP1 threonine 37/46) and mTORC2 (Akt S473) was analyzed by Western blot. Relative expression is plotted for n = 3 independent experiments per condition. B, DC were generated in the presence of GM-CSF and IL-4 and exposed to either RAPA or AZD2014 (AZD), starting on day 2 of culture. On day 7 of culture, the DC were enumerated (total number of cells per culture dish is shown). C, On day 7 of culture, control (drug vehicle-treated) CD11c + DC and CD11c + DC exposed to either RAPA or AZD2014 were treated with or without LPS (100 ng/mL) for 16 to 18 hours, washed with PBS, stained and analyzed by flow cytometry. Quantitation of CD86, B7-H1 (programmed death ligand-1) and MHC class II (I-A b ) expression (relative mean fluorescence intensity) across multiple experiments is shown. D, Bulk T cells were isolated by negative selection from B6 mouse spleen and labeled with VPD450, as described in the Materials and Methods. They were stimulated with αCD3/CD28 Dynabeads (1:2) in 96-well, round-bottom plates for 72 hours in the presence of RAPA or AZD2014 added at the start of culture. CD4 and CD8 T cell proliferation was assessed by flow cytometry. Proliferating cells were identified as CD4 + VPD450 lo or CD8 + VPD450 lo and % proliferation relative to the total parent population determined. Data are from n = 3 independent experiments *P < 0.05; **P < 0.01; ***P < 0.001. posttransplant, AZD2014, like RAPA, reduced absolute numbers of CD4 + and CD8 + (data not shown), Tfh and Treg cells ( Figure 5D ) and increased the mean Treg/memory T (Tmem) cell ratio, although not significantly ( Figure 5E ). By 21 days posttransplant (10 days after drug withdrawal), the degree of T cell suppression was reduced. Absolute numbers of both Tfh and Treg cells in AZD2014-treated mice were significantly higher compared with 7 days posttransplant. Furthermore, both Tfh and Treg cells were significantly higher in AZD2014-treated than in RAPA-treated graft recipients at 21 days ( Figure 5D ). The elevated ratio of Treg/ Tmem cells in the spleen, although preserved in RAPAtreated mice at 21 days, was no longer evident in AZD2014-treated animals ( Figure 5E ). Thus, although AZD2014 was withdrawn at the same time posttransplant as RAPA, its inhibitory effects on the T cell compartment and its influence on the Treg/Tmem ratio were less persistent.
AZD2014 and RAPA Affect Both T Cell Cytokine Production and Antidonor T Cell Proliferation Posttransplant
To assess the influence of AZD2014 on host T cell function, splenocytes were harvested 7 days posttransplant and stimulated ex vivo with phorbol 12-myristate 13-acetate (PMA) and ionomycin. T cell production of IFNγ, TNFα, and IL-2 was then assessed by mAb staining and flow cytometry. As shown in Figure 6A and B, IFNγ expression by CD4 T cells was reduced significantly in AZD2014-treated mice as in RAPA-treated mice, whereas CD8 T cell expression of IFNγ was also inhibited, although not significantly. By contrast, effects on TNFα (data not shown) and IL-2 expression by T cells were less pronounced. We also determined the influence of AZD2014 on antidonor T cell proliferative responses. The inhibitory effects of AZD2014 on ex vivo mixed leukocyte reaction were less pronounced than those of RAPA at days 7 and 21 posttransplant ( Figure 6C ). Given the elevations in absolute numbers of Tfh observed in spleens of graft recipients after withdrawal of AZD2014 compared with RAPA treatment (day 21; see Figure 5D ), we hypothesized that this might have significant consequences on downstream mediators of graft rejection, that is, total B cells, IL-10 + B cells, and donor-specific Ab (DSA). Consistent with their inhibitory effects on B cells in naive mice, both RAPA and AZD2014 suppressed absolute numbers of B cells ) increased significantly in thymi of both AZD2014-and RAPA-treated mice. H, The absolute number of Treg cells diminished in these groups. Data are from 3 animals per condition. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
in graft recipient spleens 7 days posttransplant. Although there was a relative sparing of IL-10 + B cells (B cells with regulatory function [38] [39] [40] ) in response to RAPA (Figure 7A ), this effect was not observed with AZD2014. Furthermore, by 21 days posttransplant (10 days after drug withdrawal), while total numbers of B cells increased compared with day 7, the incidence of IL-10 + B cells did not, irrespective of which mTOR inhibitor was administered.
We also examined IgG deposition in the graft and DSA levels in the serum of AZD2014-treated graft recipients. At 21 days posttransplant, although marked IgG deposition was evident in AZD2014-treated mice, only minimal deposition was detected in RAPA-treated animals ( Figure 7B ). In this heart transplant model, serum DSA levels generally peak 3 to 6 weeks posttransplant (17) . Twenty-one days posttransplant, titers of IgG1 were significantly lower in RAPA-treated compared with AZD2014-treated graft recipients that had titers of IgG1 and IgG2b like vehicle control-treated graft recipients ( Figure 7C ). Even at 100 days posttransplant, IgG2c titers remained lower in transplant recipients treated with RAPA, whereas IgG1 titers were similar between the 2 mTOR inhibitor-treated groups. No significant effects on IgG2b levels were detected.
DISCUSSION
Targeting of ATP and of the purinergic system 41 offers potential benefits in allograft rejection and tolerance. Recently, we showed 17 that AZD8055, a novel, specific ATP-competitive mTORC1/2 dual inhibitor 42 could suppress T cell proliferation and prolong mouse heart allograft survival. Despite encouraging antitumor activity in preclinical models, 43 due to high turnover in human hepatocytes and inconsistent rodent pharmacokinetics, 18 development of this agent has been discontinued and interest focused on the more potent related mTOR inhibitor AZD2014. This molecule has superior/ consistent rodent pharmacokinetics, low turnover in human hepatocytes, 18 and has been well-tolerated in phase I trials in solid tumor patients. 21, 44 Thus, we considered it appropriate to study AZD2014 to expand understanding of how novel ATP competitive dual mTOR inhibitors impact cellular and humoral alloimmunity (compared with rapalogs). In particular, based on previous rodent studies showing an important role for mTORC2 in B cell maturation, homeostasis, and Ab production, we hypothesized that AZD2014 might have (unique) advantages over RAPA in terms of inhibitory effects on B cells, circulating DSA levels, and Ab deposition in the graft-variables that we did not examine in our AZD8055 study. 17 Here, we show for the first time that AZD2014 exerts multiple effects on immune cell populations, thus (i) inhibiting myeloid DC generation and T cell proliferation in vitro; (ii) markedly depleting thymocytes in vivo, although enriching for thymic Treg cells; and (iii) reducing innate and adaptive immune cell populations (DC, NK cells, NKT cells, T cell subsets, and B cells) in secondary lymphoid tissue. The greater potency of RAPA observed is consistent with a reported IC50 for mTOR of 0.1 and 2.8 nM for RAPA and AZD2014, respectively. We know from the others' work that doses of 7.5 to 15 mg/kg of AZD2014 administered to mice by oral gavage produced a C max from 1 to 10 μmol/L in plasma. 20 Based on these observations, one would expect a dose of 10 mg/kg of AZD2014 administered intraperitoneally to produce peak plasma and intracellular drug concentrations above 2000 nM (2 μmol/L). Furthermore, in the first-in-human pharmacokinetic study of AZD2014, the maximum tolerated dose was 50 mg twice daily taken orally. 44 Using a formula for dose translation based on body surface area, a dose of 10 mg/kg delivered to mice is equivalent to the maximum tolerated dose in humans (based on a body weight of 60 kg). 45 Taken together, these known pharmacokinetic properties of AZD2014, justified administering 10 mg/kg twice daily, a dose twentyfold higher than RAPA, in the current study. AZD2014 significantly prolonged major histocompatibility complex-mismatched organ allograft survival, while inhibiting effector T cell responses to donor, reducing Tfh cells and B cells, but exhibiting little effect on DSA production. Significantly, 10 days after drug withdrawal, both Tfh cell numbers and DSA (IgG1, IgG2b and IgG2c) titers in AZD2014-treated graft recipients were higher than that in RAPA-treated recipients and did not differ significantly from levels in vehicle-treated controls.
We observed severe thymic atrophy and profound reduction in absolute thymocyte numbers, with an increased incidence of CD4
+ Treg cells in AZD2014-treated mice. In contrast, relative Treg cell enrichment was not seen in the spleen in response to either mTOR inhibitor. These results are consistent with effects of RAPA in lymphocytereplete mice. 46 In these latter studies, administration of RAPA inhibited homeostatic and alloAg-induced Treg cell proliferation in the spleen and lymph nodes (the thymus was not examined). Furthermore, Treg cells and conventional T cells were depleted similarly. By contrast, in a separate study, 2 weeks of RAPA administration enriched for Treg cells in both the thymus and spleen. 47 Interestingly, Tfh cells, a subset of T cells that stimulates germinal center (GC) B cells and Ab class switching, was also suppressed by AZD2014 or RAPA during the drug administration period. Although previous studies 11 have suggested that Tfh, like Treg cells, use less glycolysis, mitochondrial respiration and as a consequence, mTOR function than Th1 cells, AZD2014 and RAPA both suppressed Tfh effectively. This is consistent with recent data 48 demonstrating that glucose metabolism and both mTORC1 and mTORC2 signaling are essential for Tfh differentiation and GC reaction in Peyer patches. In the latter study, mTORC2 was uniquely required for normal Tfh cell localization in PP, expression of Forkhead box protein 01 (Fox01) targets, and nuclear exclusion of Fox01 upon inducible T cell costimulator ligation. By contrast, in the present investigation, 10 days after drug withdrawal, repopulation of the T cell compartment was more robust in graft recipients given AZD2014 than those given RAPA. Furthermore, statistically significant differences in the number of Tfh (and to a lesser extent Treg cells) were clearly evident. One possible explanation for these differences is that reversal of both mTORC1 and mTORC2 inhibition upon AZD2014 withdrawal may trigger a greater proliferative response in T cells (particularly in Tfh) than reversal of selective mTORC1 inhibition after RAPA withdrawal. FIGURE 5. AZD2014 prolongs heart allograft survival. A, The protocol used for AZD2014 (AZD) or RAPA administration after heart transplantation. Starting on day 3 posttransplant, a 9-day course of either AZD2014 (10 mg/kg, i.p. twice daily), RAPA (1 mg/kg, i.p. daily), or drug vehicle was administered. B, Actuarial graft survival curves; numbers of transplanted mice in each group are shown in parentheses. C, Histological appearance of heart allografts (H & E stain; horizontal bar indicates 200 μm). D-E, T cell populations (Tfh and Treg cells) in the spleen and Treg:Tem ratios 7 days and 21 days posttransplant. n = 3 graft recipients per group *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Given the importance of humoral immunity in long-term allograft survival, the influence of mTOR inhibitors on B cells and subsequent Ab production has been the subject of considerable recent interest. RAPA can strongly inhibit B cell responses and Ig production in vitro. 49 We found that although RAPA suppressed the total number of host B cells posttransplant, it simultaneously preserved the incidence of IL-10 + B cells and suppressed titers of circulating DSA (IgG1 and IgG2c) and IgG deposition within the graft. Others have shown that RAPA increases graft-infiltrating IL-10 + transforming growth factor β + Regulatory B cells (Breg) in a mouse tracheal transplant model. 50 Thus, based on these preclinical data, one might expect RAPA to exert suppressive effects on human pathogenic complement-fixing IgG1 and IgG3 DSA generation posttransplant. 51 Paradoxically, however, compared with standard calcineurin inhibitor-based immunosuppression, several retrospective analyses have documented a higher incidence of de novo DSA in kidney transplant patients treated with mTOR inhibitors. 5, 52, 53 Using a mouse lymphocytic choriomeningitis virus model with modulation of mTOR signaling by RNAi, B cells were found recently to be the primary cell targets of RAPA, with reduced Tfh formation due to lower GC B cell responses. 54 The differential effects of RAPA and AZD2014 on IL-10 + B cells is another interesting finding that warrants further investigation. In contrast to RAPA, although AZD2014 was also able to suppress total B cells, it did not preserve IL-10 + B cells or prevent alloAb generation and deposition. The distinctions we observed between RAPA and AZD2014 in prolongation of allograft survival, as well as the greater durability of immunosuppression mediated by RAPA after its withdrawal, may reflect pharmacologic differences and also differences in the reversibility of the effects of these agents on T cells. Based on our previous pharmacokinetic studies comparing AZD8055 and RAPA, coupled with the small body of pharmacologic literature on AZD2014, we hypothesize that differences in tissue and cellular penetration, mTOR affinity and elimination half-life could account for the differential effects on alloimmune reactivity and graft survival. Alternatively, RAPA might uniquely affect several non-mTORC1 pathways important in T cell function. It is also possible that dual inhibition (mTORC1 and mTORC2) might be less immunosuppressive than mTORC1 inhibition in certain immune cells. Analysis of cell signaling pathways in allografts and/or lymphoid tissue at various times after drug withdrawal would allow dissection of the molecular differences between these 2 mTOR inhibitors. Nonetheless, a favorable toxicity profile of ATP-competitive dual mTORC1/2 inhibition would justify testing these novel agents with other immunosuppressive strategies (ie, costimulation blockade or calcineurin inhibition) in organ transplantation.
